RESEARCH ARTICLE
Targeting TRPV3 for the Development of Novel Analgesics
Susan M. Huang1, Man-Kyo Chung*, 1
Article Information
Identifiers and Pagination:
Year: 2013Volume: 6
First Page: 119
Last Page: 126
Publisher ID: TOPAINJ-6-119
DOI: 10.2174/1876386301306010119
Article History:
Received Date: 09/08/2012Revision Received Date: 09/08/2012
Acceptance Date: 16/08/2012
Electronic publication date: 08/3/2013
Collection year: 2013
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Decades of characterization of the transient receptor potential vanilloid subtype 1 (TRPV1) have led to the realization of its central role in thermosensation and pain perception. A large number of pharmaceutical companies have had interest in developing TPRV1 antagonists for the treatment of pain. The subsequent discovery of multiple other members of this TRPV family has not gone unnoticed. TRPV3 exhibits approximately 40% homology to TRPV1, and has common as well as distinct features from TRPV1 in channel physiology, expression and function. Here we review the current understanding of TRPV3 channel biology, activation, sensitization and the consequences of TRPV3 manipulation for thermosensation and nociception, as well as additional considerations regarding the expression of TRPV3 in the skin. We weigh in on the available evidence in the context of potential development of TRPV3 modulating agents as analgesics.